Jason Chihcheng Wu

US Patent:

8222270, Jul 17, 2012

Filed:

Jul 8, 2011

Appl. No.:

13/179315

Inventors:

Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

Assignee:

Medicis Pharmaceutical Corporation - Scottsdale AZ

International Classification:

A01N 43/42
A01N 43/52

US Classification:

514290, 514393

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i. e. , imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U. S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U. S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

US Patent:

8236816, Aug 7, 2012

Filed:

Jul 12, 2011

Appl. No.:

13/181499

Inventors:

Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

Assignee:

Medicis Pharmaceutical Corporation - Scottsdale AZ

International Classification:

A01N 43/42
A01N 43/52

US Classification:

514290, 514393

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i. e. , imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U. S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U. S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

US Patent:

8242155, Aug 14, 2012

Filed:

Jul 13, 2011

Appl. No.:

13/182433

Inventors:

Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

Assignee:

Medicis Pharmaceutical Corporation - Scottsdale AZ

International Classification:

A01N 43/52
A01N 43/42

US Classification:

514393, 514290

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i. e. , imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U. S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U. S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

US Patent:

8299109, Oct 30, 2012

Filed:

Jul 13, 2011

Appl. No.:

13/182433

Inventors:

Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

Assignee:

Medicis Pharmaceutical Corporation - Scottsdale AZ

International Classification:

A01N 43/52
A01N 43/42

US Classification:

514393, 514290

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i. e. , imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U. S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U. S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

US Patent:

20110021555, Jan 27, 2011

Filed:

Dec 11, 2009

Appl. No.:

12/636613

Inventors:

Michael T. Nordsiek - Berwyn PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Downingtown PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn J. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

Assignee:

Graceway Pharmaceuticals, LLC - Bristol TN

International Classification:

A61K 31/4745
A61P 17/12

US Classification:

514293

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

US Patent:

20110207766, Aug 25, 2011

Filed:

Apr 30, 2010

Appl. No.:

12/771076

Inventors:

Michael T. Nordsiek - Berwyn PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Downingtown PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

Assignee:

Graceway Pharmaceuticals, LLC. - Bristol TN

International Classification:

A61K 31/4745
A61P 17/12

US Classification:

514293

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

US Patent:

20110257217, Oct 20, 2011

Filed:

Jul 8, 2011

Appl. No.:

13/179363

Inventors:

Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

International Classification:

A61K 31/4745
A61P 17/12

US Classification:

514293

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

US Patent:

20110257219, Oct 20, 2011

Filed:

Jul 12, 2011

Appl. No.:

13/181507

Inventors:

Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US

Assignee:

Graceway Pharmaceuticals, LLC - Bristol TN

International Classification:

A61K 31/437
A61P 35/00
A61P 17/02

US Classification:

514293

Abstract:

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara 5% imiquimod cream to treat actinic keratosis are also disclosed and described.